Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Common Equity: 2012-2016

Historic Common Equity for Tvardi Therapeutics (TVRD) over the last 5 years, with Dec 2016 value amounting to $50.7 million.

  • Tvardi Therapeutics' Common Equity rose 37.98% to $99.1 million in Q3 2017 from the same period last year, while for Sep 2017 it was $99.1 million, marking a year-over-year increase of 37.98%. This contributed to the annual value of $50.7 million for FY2016, which is 51.71% down from last year.
  • Latest data reveals that Tvardi Therapeutics reported Common Equity of $50.7 million as of FY2016, which was down 51.71% from $105.0 million recorded in FY2015.
  • Tvardi Therapeutics' Common Equity's 5-year high stood at $105.0 million during FY2015, with a 5-year trough of -$58.1 million in FY2012.
  • Over the past 3 years, Tvardi Therapeutics' median Common Equity value was $51.7 million (recorded in 2014), while the average stood at $69.1 million.
  • Per our database at Business Quant, Tvardi Therapeutics' Common Equity soared by 195.54% in 2014 and then tumbled by 51.71% in 2016.
  • Tvardi Therapeutics' Common Equity (Yearly) stood at -$58.1 million in 2012, then grew by 6.98% to -$54.1 million in 2013, then skyrocketed by 195.54% to $51.7 million in 2014, then surged by 103.33% to $105.0 million in 2015, then plummeted by 51.71% to $50.7 million in 2016.